HEMATOLOGY

In an interview with Targeted Oncology, Lee Greenberger, PhD, discussed some of the latest, interesting research that caught his attention in 2023 and what community oncologists should know about the space as we move into 2024.

Clinicians discuss the importance of early detection in patients with MDS as well as providing insights into some of the unmet needs in MDS, such as a better understanding of the role of molecular alterations and its specific impact in MDS.

Hana Safah, MD explains how the risk stratification for MDS has evolved over time and provides an in-depth of the current risk stratification tools, IPSS, IPSS-R and IPSS-M.

Drs Safah and Koprivnikar review updates made to the WHO and ICC guidelines when classifying MDS as well as discussing the impact of molecular alterations when treating MDS.

Iopofosine I-131 showed impressive results in a study for patients with advanced Waldenstrom's macroglobulinemia, achieving a major response rate of 61%.

New treatments, including luspatercept-aamt, have been added to the treatment algorithm of patients with low-risk myelodysplastic syndrome in 2020.

Yazan Madanat, MD, comments on the updates that were recently presented at ASH 2023 for the management of lower-risk MDS and discusses the impact of emerging therapies.

In an interview with Targeted Oncology, Daniel Wolff, MD, discussed findings from the phase 2 AGAVE-201 trial evaluating axatilimab as a potential treatment option for patients with chronic graft-vs-host disease.

Dipti Patel-Donnelly, MD, discusses the gaps between academic centers and community oncology regarding treatments for hematologic malignancies.

Mazyar Shadman, MD, MPH, explains the current standard-of-care treatment for patients with chronic lymphocytic leukemia and details the factors he considers when choosing an appropriate therapy.

Experts review best practices for identifying and diagnosing patients with lower-risk MDS.

John M. Burke, MD, discusses the 2 phase 3 trials presented at the 2023 ASH Annual Meeting that have potential to be practice changing for patients with multiple myeloma and chronic lymphocytic leukemia.

The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.

The high-precision cellular product Orca-Q demonstrated early signals of clinical activity as well as an acceptable safety profile for patients undergoing haploidentical stem cell transplantation without posttransplant cyclophosphamide.

Results from an ongoing phase 2 study show the viability for the use of zanubrutinib after patients with previously treated B-cell malignancies are deemed intolerant to the next-generation Bruton tyrosine kinase inhibitor acalabrutinib.

Data from the phase 3 APPLY-PNH trial show comprehensive control of intravascular and extravascular hemolysis with iptacopan in patients with paroxysmal nocturnal hemoglobinuria and persistent anemia.

The 3-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid refractory or dependent chronic graft-versus-host disease benefited more with ruxolitinib compared with best available treatment.

Axatilimab induced rapid and durable responses with an acceptable toxicity profile at all doses analyzed with highest efficacy observed at the 0.3-mg/kg dose in patients with recurrent or refractory chronic graft-vs-host disease.

Use of oral decitabine and cedazuridine vs intravenous/subcutaneous standard-of-care parenteral hypomethylating agents showed similar safety results but also improved treatment in in patients with myelodysplastic syndrome.

A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.

CT071, a chimeric antigen receptor T-cell therapy candidate, had an investigational new drug application cleared by the FDA for patients with relapsed/refractory multiple myeloma and primary plasma cell leukemia.

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

A glimpse into the ever-changing treatment landscape of DLBCL, exploring frontline therapy options and the potential for tailoring treatments based on novel agents and randomized trials.

Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.

A comprehensive exploration of CAR T-cell therapy and additional agents such as loncastuximab in relapsed/refractory DLBCL, emphasizing clinical findings and treatment considerations.